GlassScriptPhysician profile
Melchor Ng Lim
NPI 1932147113
$5,940.38
in general payments reported to CMS, 2019-2025
33 companies · $431 in 2025
The $431 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,286 · 2020: $566 · 2021: $1,077 · 2022: $1,061 · 2023: $675 · 2024: $845 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,950.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,237.83 | 2019-2025 | |
| Pfizer INC. | $876.60 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $603.49 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $437.91 | 2019-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $386.38 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $377.67 | 2021-2025 | Verquvo |
| Abbott Laboratories | $353.71 | 2019-2024 | Cardiomems, Amplatzer Amulet |
| Astrazeneca Pharmaceuticals LP | $159.46 | 2019-2025 | Farxiga, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $151.22 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.74 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $135.12 | 2020-2024 | |
| Actelion Pharmaceuticals US, INC. | $120.23 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $110.72 | 2023-2024 | Assure Wcd |
| Regeneron Healthcare Solutions, INC. | $110.24 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.37 | 2021-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $87.11 | 2020-2024 | Amvuttra |
| Esperion Therapeutics, INC. | $74.57 | 2020-2021 | |
| Boston Scientific Corporation | $72.99 | 2019-2023 | |
| Astellas Pharma US INC | $64.72 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $53.43 | 2023-2024 | Inpefa |
| Amgen INC. | $48.35 | 2019-2020 | |
| Abiomed | $37.93 | 2025 | |
| Novo Nordisk INC | $31.38 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Biosense Webster, INC. | $26.13 | 2019 | |
| Innovation Technologies INC | $19.65 | 2022 | |
| United Therapeutics Corporation | $19.58 | 2025 | Tyvaso |
| Insmed, INC. | $18.92 | 2025 | Arikayce |
| Irhythm Technologies, INC. | $18.03 | 2020 | |
| Edwards Lifesciences Corporation | $16.36 | 2022 | |
| Inspire Medical Systems, INC. | $16.00 | 2025 | Inspire |
| Lundbeck LLC | $14.01 | 2019 | |
| Bardy Diagnostics, INC. | $11.93 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melchor Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.